Type of security: Stock
Sector: Health Care
Industry: Major Pharmaceuticals
The data is delayed by 15 minutes.
AGIO is in the long-term down -58% below S&P in 6 years.
Description: Agios Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the development and commercialization of therapeutics in the field of cancer metabolism and inborn errors of metabolism (IEMs) in the United States. Its product candidates include AG-221, an oral inhibitor of the mutated isocitrate dehydrogenase (IDH) 2 protein for the treatment of patients with cancers that harbor IDH2 mutations, as well as for the Type II D-2 hydroxyglutaric aciduria treatment; and AG-120, an oral inhibitor of the mutated IDH1 protein for the treatment of patients with cancers that harbor IDH1 mutations. The company is also developing AG-348, an oral small molecule activator of PKR enzyme for the treatment of patients with pyruvate kinase deficiency. It has a collaboration agreement with Celgene Corporation to discover, develop, and commercialize disease-altering therapies in oncology. Agios Pharmaceuticals, Inc. was founded in 2007 and is based in Cambridge, Massachusetts.
|Shares Outstanding||EPS||-6||EPS Growth - 4 Quarters||EPS Growth - Q/Q|
|EPS Growth - Y/Y||Sales Growth - 4 Quarters||306.63%||Sales Growth - Q/Q||133.68%||P/E||-8.63|
|P/E To EPS Growth||P/S||P/BV||Price/Cash Per Share|
|Price/Free Cash Flow||ROA||-9.74%||ROE||-10.83%||ROI|
|Current Ratio||10.01||Quick Ratio||Long Term Debt/Equity||Debt Ratio||0.09|
|Gross Margin||Operating Margin||-51.61%||Net Profit Margin||-50.7%||Dividend Payout Ratio|
|Cash From Financing Activities||1.82 M||Cash From Investing Activities||44.99 M||Cash From Operating Activities||-25.59 M||Gross Profit|
|Net Profit||-4.96 M||Operating Profit||-5.2 M||Total Assets||474.34 M||Total Current Assets||364.14 M|
|Total Current Liabilities||36.38 M||Total Debt||Total Liabilities||47.52 M||Total Revenue||34.2 M|
|High 52 week||75.11||Low 52 week||42.73||Last close||62.35||Last change||5.93%|
|RSI||68.62||Average true range||2.74||Beta||1.94||Volume||828.59 K|
|Simple moving average 20 days||13.04%||Simple moving average 50 days||18.89%||Simple moving average 200 days||3.15%|
|Performance Week||5.16%||Performance Month||20.07%||Performance Quart||-5.23%||Performance Half||4.56%|
|Performance Year||26.83%||Performance Year-to-date||35.22%||Volatility daily||2.87%||Volatility weekly||6.41%|
|Volatility monthly||13.13%||Volatility yearly||45.49%||Relative Volume||130.51%||Average Volume||563.62 K|
|New High||New Low|
2019-03-16 09:30:01 | Why Is Agios Pharmaceuticals AGIO Up 13.2% Since Last Earnings Report?
2019-03-06 14:01:46 | All You Need To Know About Agios Pharmaceuticals, Inc.’s NASDAQ:AGIO Financial Health
2019-02-25 07:00:00 | Agios Reports Updated Data from Phase 1 Study of Ivosidenib in Combination with Azacitidine Demonstrating Deep and Durable Responses in Newly Diagnosed IDH1 Mutant Acute Myeloid Leukemia AML Patients
2019-02-22 07:25:00 | Analysis: Positioning to Benefit within Quest Diagnostics, Autodesk, Agios Pharmaceuticals, AMN Healthcare Services, Vistra Energy, and Helen of Troy — Research Highlights Growth, Revenue, and Consolidated Results
2019-02-21 09:34:02 | Agios' Tibsovo Gets FDA Priority Review in First-Line Cancer
2019-02-20 15:43:40 | Edited Transcript of AGIO earnings conference call or presentation 14-Feb-19 1:00pm GMT
2019-02-20 07:00:00 | Agios Announces FDA Acceptance of Supplemental New Drug Application for TIBSOVO® ivosidenib for the Treatment of Patients with Newly Diagnosed Acute Myeloid Leukemia with an IDH1 Mutation Not Eligible for Standard Therapy
2019-02-15 14:25:07 | Agios AGIO Q4 Earnings Beat, Tibsovo Sales Push Up Stock
2019-02-14 12:01:58 | Agios Pharmaceuticals Inc AGIO Q4 2018 Earnings Conference Call Transcript
2019-02-14 09:10:02 | Agios Pharmaceuticals AGIO Reports Q4 Loss, Tops Revenue Estimates
2019-02-14 08:10:46 | Agios Pharmaceuticals: 4Q Earnings Snapshot
2019-02-14 07:00:00 | Agios Reports Fourth Quarter and Full Year 2018 Financial Results
2019-02-11 12:09:14 | Agios ex-CEO joins GV as life sciences investment team's co-head
2019-02-08 08:04:12 | See what the IHS Markit Score report has to say about Agios Pharmaceuticals Inc.
2019-01-29 13:52:34 | Have Insiders Been Selling Agios Pharmaceuticals, Inc. NASDAQ:AGIO Shares?
2019-01-29 08:05:17 | See what the IHS Markit Score report has to say about Agios Pharmaceuticals Inc.
2019-01-22 08:04:06 | See what the IHS Markit Score report has to say about Agios Pharmaceuticals Inc.
2019-01-10 12:07:29 | 5 Biotech Stocks That Could Face M&A Next!
2019-01-09 08:05:49 | See what the IHS Markit Score report has to say about Agios Pharmaceuticals Inc.
2018-12-14 12:03:39 | Our Take On Agios Pharmaceuticals, Inc.’s NASDAQ:AGIO CEO Salary
2018-12-13 07:20:00 | Market Trends Toward New Normal in DXC Technology, Patterson Companies, Lumentum, DSW, Agios Pharmaceuticals, and Six Flags Entertainment Corporation New — Emerging Consolidated Expectations, Analyst Ratings
2018-12-13 03:20:00 | Hedge Funds Are Selling Agios Pharmaceuticals Inc AGIO
2018-12-08 17:36:00 | Could These Be the Next 2 Biotech Buyouts?
2018-12-03 10:30:00 | Agios Presents Updated Data from the Ivosidenib Phase 1 Dose-Escalation and Expansion Trial in IDH1 Mutant Positive Patients with Newly Diagnosed Acute Myeloid Leukemia AML Ineligible for Standard Treatment and Myelodysplastic Syndrome MDS
2018-12-03 10:15:00 | Agios Announces Updated Data from Phase 1 Study of Ivosidenib or Enasidenib in Combination with Standard Induction and Consolidation Chemotherapy in Newly Diagnosed AML Patients With an IDH Mutation
2018-11-14 06:55:00 | Today's Research Reports on Trending Tickers: Exelixis and Agios Pharmaceuticals
2018-11-08 08:00:00 | New Research Coverage Highlights John B. Sanfilippo & Son, Axcelis Technologies, Cogent Communications, Star Bulk Carriers, Agios Pharmaceuticals, and MDC Partners — Consolidated Revenues, Company Growth, and Expectations for 2018
2018-11-08 06:00:00 | 3 Biotech Stocks Poised for Big Rebounds
2018-11-02 13:01:05 | Agios AGIO Q3 Earnings Beat, Tibsovo Sales Drive Stock
2018-11-01 14:15:36 | Edited Transcript of AGIO earnings conference call or presentation 1-Nov-18 12:00pm GMT
2018-11-01 10:41:02 | Agios Pharmaceuticals AGIO Reports Q3 Loss, Tops Revenue Estimates
2018-11-01 09:20:05 | Agios to Present Updated Clinical Data at the 2018 ASH Annual Meeting
2018-11-01 08:22:23 | Agios Pharmaceuticals: 3Q Earnings Snapshot
2018-11-01 08:00:00 | Today's Research Reports on Trending Tickers: Agios Pharmaceuticals and Incyte
2018-11-01 07:00:00 | Agios Reports Third Quarter 2018 Financial Results
2018-10-26 08:05:31 | See what the IHS Markit Score report has to say about Agios Pharmaceuticals Inc.
2018-10-19 11:44:03 | Agios Rides on Tibsovo Approval Amid Reliance on Celgene
2018-10-11 08:06:17 | See what the IHS Markit Score report has to say about Agios Pharmaceuticals Inc.
2018-10-06 08:06:16 | See what the IHS Markit Score report has to say about Agios Pharmaceuticals Inc.
2018-10-05 08:06:28 | See what the IHS Markit Score report has to say about Agios Pharmaceuticals Inc.